Impoyz generic
Impoyz is an anti-inflammatory drug that contains the active ingredient clobetasol propionate. It is owned by Primus Pharms and was first authorized for market use on 28 November, 2017. The drug, available in cream topical dosage forms, holds a total of 4 patents.
When will Impoyz generic be available?
The generic version of Impoyz could possibly be released after 11 March, 2035. This follows the expiration of the last patent, US9855334 titled 'Topical compositions comprising a corticosteroid', expiring on the aforementioned date.
Impoyz uses
Impoyz is used in the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. This includes conditions such as plaque psoriasis and psoriasis. Its active ingredient, clobetasol propionate, contributes to its effectiveness.
Impoyz patent expiration
Impoyz has four main drug patents with the last one, US9855334 titled 'Topical compositions comprising a corticosteroid', expiring on 11 March, 2035, which would lead to the availability of Impoyz generic. Below are the details of the patent: